Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 8OTHER_GOV 1NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Refractory Differentiated Thyroid Gland Carcinoma 1

Interventions

Radiotherapy 138Cyclophosphamide 108Cisplatin 103Doxorubicin 99Vincristine 76Filgrastim 60Etoposide 58Paclitaxel 56Carboplatin 53Fluorouracil 51Methotrexate 49Dexamethasone 49Cytarabine 43Prednisone 42Leucovorin 40Granulocyte Colony-Stimulating Factor 34Docetaxel 34Radiation 31Specimen Handling 30Tamoxifen 27Daunorubicin 27Magnetic Resonance Spectroscopy 26Calcium Dobesilate 26Ifosfamide 25Mercaptopurine 24Gemcitabine 24Platinum 22Goserelin 221,2-diaminocyclohexaneplatinum II citrate 22Chemotherapy, Adjuvant 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × NETWORK × trametinib × Clear all
NCT06475989 2026-05-15

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Eastern Cooperative Oncology Group

Phase 3 Recruiting
264 enrolled
Head & Neck

Refractory Differentiated Thyroid Gland Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡